已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study

艾瑞布林 医学 耐受性 危险系数 内科学 肿瘤科 转移性乳腺癌 乳腺癌 化疗 临床终点 无进展生存期 回顾性队列研究 外科 癌症 不利影响 临床试验 置信区间
作者
Weiwei Huang,Chenxi Wang,Lili Wang,Yangkun Shen,Qi Chen,Zhijian Huang,Jian Liu,Xiaoyan Lin,Fan Wu,Xinhua Chen,Nani Li,Yi Hong,Mulan Chen,Jieyu Li,Chuanzhong Huang
出处
期刊:Frontiers in Cell and Developmental Biology [Frontiers Media]
卷期号:12
标识
DOI:10.3389/fcell.2024.1313610
摘要

Background: Patients with Triple-negative breast cancer (TNBC) face a poor prognosis and limited therapeutic options. Current data on eribulin usage to treat TNBC is scarce. Therefore, we sought to compare the feasibility and tolerability of eribulin-based regimens with other chemotherapy regimens in patients with TNBC. Method: This retrospective study was conducted at Fujian Medical University Cancer Hospital and included 159 patients with TNBC enrolled between October 2011 and January 2023. Patients underwent treatment with eribulin-based and other chemotherapy regimens. The study’s primary endpoints were progression-free survival (PFS) and overall survival (OS), while its secondary endpoint was objective response rate (ORR), disease control rate (DCR), and safety. Tumour response was assessed using RECIST V.1.1 criteria. Results: Of the 159 participants in the study, 42 individuals (26.4%) received treatment with eribulin, whereas 117 participants (73.6%) were administered alternative chemotherapy regimens, which included nab-paclitaxel-based therapy (n = 45) and platinum-based therapy (n = 51). The follow-up period for all patients ended on 31 December 2022, and the median follow-up time was 18.3 months (range:0.7–27.5). Following propensity score matching (PSM), eribulin-based treatment resulted in longer median progression-free survival compared to platinum-based (hazard ratio (HR) = 0.41, p = 0.006), nab-paclitaxel-based (hazard ratio = 0.36, p = 0.001) and other chemotherapy (HR = 0.39, p < 0.001). Also, eribulin induced a remarkable prolongation of the median overall survival duration in all three comparative groups. The group receiving eribulin treatment showed significantly reduced incidences of any grade of anaemia, peripheral neuropathy, nausea and vomiting, and hair loss compared to other chemotherapy groups. Conclusion: For the salvage treatment of advanced TNBC, treatment with eribulin produced longer median PFS and OS than other chemotherapy regimens, with a well-tolerated safety profile. Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
CodeCraft应助十二平均律采纳,获得10
刚刚
1秒前
JamesPei应助花凉采纳,获得10
2秒前
2秒前
2秒前
3秒前
cc完成签到,获得积分10
3秒前
moon完成签到,获得积分10
3秒前
3秒前
今后应助坚定涵柏采纳,获得10
3秒前
悦耳的小鸽子完成签到,获得积分10
3秒前
4秒前
hutingting完成签到 ,获得积分10
4秒前
小小发布了新的文献求助10
4秒前
5秒前
研友_Zrlk7L完成签到,获得积分10
7秒前
7秒前
Fionaaaaaaa发布了新的文献求助10
7秒前
西瓜西瓜发布了新的文献求助10
7秒前
慕青应助li采纳,获得10
7秒前
iii发布了新的文献求助10
8秒前
怪僻完成签到,获得积分10
8秒前
9秒前
12秒前
Tr0c应助冷酷映波采纳,获得30
13秒前
13秒前
第二支羽毛完成签到 ,获得积分10
13秒前
小蘑菇应助AR采纳,获得10
15秒前
灵巧大地发布了新的文献求助10
15秒前
15秒前
16秒前
16秒前
linlin完成签到,获得积分10
17秒前
大力的冬萱完成签到,获得积分10
17秒前
西瓜西瓜发布了新的文献求助10
17秒前
ding应助白昼采纳,获得10
18秒前
萝卜完成签到,获得积分10
19秒前
snowman发布了新的文献求助10
21秒前
鲁成危完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6522497
求助须知:如何正确求助?哪些是违规求助? 8315739
关于积分的说明 17790940
捐赠科研通 5624670
什么是DOI,文献DOI怎么找? 2927969
邀请新用户注册赠送积分活动 1904739
关于科研通互助平台的介绍 1764766